# Robert Weigle

> Robert K. Weigle is a medical device and diagnostics executive with more than 25 years of experience taking healthcare products from pre-clinical research to commercial launch. He is CEO of NOW Diagnostics, an independent board member of Tenon Medical, and a former entrepreneur-in-residence at DigitalDx Ventures. He led Benvenue Medical as CEO for over a decade, raising more than $200 million and launching spine devices in two markets, and later ran saliva-based diagnostics companies focused on cancer detection. His career spans Fortune 500 names like Johnson & Johnson and Baxter as well as a string of venture-backed startups.

- **Role:** CEO at NOW Diagnostics; Board Member at Tenon Medical, Inc.
- **Organizations:** NOW Diagnostics (NOWDx), Tenon Medical, Inc., AeenaDX / Prime Genomics, DigitalDx Ventures, Benvenue Medical, TherOx, Inc., Cardiac Pathways, Baxter Healthcare, Johnson & Johnson
- **Nationality:** American
- **Education:** BA, Political Science, University of California, Berkeley, Executive coursework, Kellogg School of Management (Northwestern), Executive coursework, Darden School of Business (Baxter courses)
- **Known for:** Led Benvenue Medical as CEO from 2009 to 2020, raising over $200 million in funding, Took Benvenue devices from pre-clinical through clinical trials to commercial launch in two distinct spine markets, Drove a first full-year run rate exceeding $1 million per month at Benvenue

## Career timeline

- **1990s** — Senior sales and marketing roles at Johnson & Johnson, Baxter, Camino, and Aesculap
- **2009** — Became CEO and director of Benvenue Medical
- **2020** — Stepped down from Benvenue after 11 years; became Entrepreneur in Residence at DigitalDx Ventures
- **2020** — Named CEO of Prime Genomics (later AeenaDX), a saliva-based diagnostics company
- **2022** — Joined the board of directors of Tenon Medical, Inc. as an independent director
- **2023** — Became CEO of NOW Diagnostics (NOWDx)

## Achievements

- Led Benvenue Medical as CEO from 2009 to 2020, raising over $200 million in funding
- Took Benvenue devices from pre-clinical through clinical trials to commercial launch in two distinct spine markets
- Drove a first full-year run rate exceeding $1 million per month at Benvenue
- Personally responsible for over $130 million in private-placement fundraising across his career
- Drove sales exceeding $100 million across multiple medical device companies
- Managed FDA clearances, clinical trials, reimbursement strategies, and strategic exits
- Served on Tenon Medical's Audit Committee and chaired its Nominating and Corporate Governance Committee

## Latest updates

- **2023-04** — Became CEO of NOW Diagnostics (NOWDx)
- **2022-05** — Appointed independent director on the board of Tenon Medical, Inc.

## Links

- Website: https://tenonmed.com
- LinkedIn: http://www.linkedin.com/in/robert-weigle-3479224

---

Profile page: https://yespress.io/robert-weigle
Published by YesPress — https://yespress.io
Last updated: 2026-06-08